Losoxantrone

Losoxantrone
Identifiers
	IUPAC name 7-Hydroxy-2-{2-[(2-hydroxyethyl)amino]ethyl}-5-({2-[(2-hydroxyethyl)amino]ethyl}amino)dibenzo[cd,g]indazol-6(2H)-one;
CAS Number	88303-60-0 ;
PubChem CID	72116;
ChemSpider	65094 ;
UNII	47KPH00809;
CompTox Dashboard (EPA)	DTXSID60236949 ;
Chemical and physical data
Formula	C22H27N5O4
Molar mass	425.489 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1cc-2c(c(c1)O)C(=O)c3c(ccc4c3c2nn4CCNCCO)NCCNCCO;
	InChI InChI=InChI=1S/C22H27N5O4/c28-12-9-23-6-7-25-15-4-5-16-20-19(15)22(31)18-14(2-1-3-17(18)30)21(20)26-27(16)11-8-24-10-13-29/h1-5,23-25,28-30H,6-13H2 ; Key:YROQEQPFUCPDCP-UHFFFAOYSA-N ;

Losoxantrone (biantrazole) is an anthroquinone anthrapyrazole antineoplastic agent and analog of mitoxantrone.^[1]^[2] It is also sometimes known as DuP 941.^[3]

References

^ Showalter, H. D. H.; Johnson, J. L.; Hoftiezer, J. M.; Turner, W. R.; Werbel, L. M.; Leopold, W. R.; Shillis, J. L.; Jackson, R. C.; Elslager, E. F. (1987). "Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias". Journal of Medicinal Chemistry. 30: 121. doi:10.1021/jm00384a021.
^ Beylin, V. G.; Colbry, N. L.; Goel, O. P.; Haky, J. E.; Johnson, D. R.; Johnson, J. L.; Kanter, G. D.; Leeds, R. L.; Leja, B.; Lewis, E. P.; Rithner, C. D.; Showalter, H. D. H.; Sercel, A. D.; Turner, W. R.; Uhlendorf, S. E. (1989). "Anticancer anthrapyrazoles. Improved syntheses of clinical agents CI-937, CI-941, and piroxantrone hydrochloride". Journal of Heterocyclic Chemistry. 26: 85. doi:10.1002/jhet.5570260117.
^ Leteurtre, F.; Kohlhagen, G.; Paull, K. D.; Pommier, Y. (17 August 1994). "Topoisomerase II Inhibition and Cytotoxicity of the Anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute Preclinical Antitumor Drug Discovery Screen" (PDF). JNCI Journal of the National Cancer Institute. 86 (16): 1239–1244. doi:10.1093/jnci/86.16.1239.